Skip to Content

Prolonged Progression-Free Survival in Patients with Advanced Ovarian Cancer

Results from ASCO23 provide encouraging evidence for a novel treatment approach using durvalumab and olaparib in addition to the standard of care for patients with advanced ovarian cancer.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top